Across four funding rounds, the BMTH program backed 49 innovation projects, and investments from the program focused on supporting proof-of-concept to commercial development of biomedical and medical technologies.
With the program now complete, analysis makes it clear that this objective has been met. The program has supported 49 companies with $39.1 million of funds from the MRFF, leveraging $50.8 million of additional direct and indirect sector contributions for projects. This has led to more than $590 million in follow-on funding for these projects – with the vast majority coming from private sources.
When the program concluded in 2023, eleven products had received regulatory approvals and are available in market, with more expected in the future as research activities complete and market entry activities increase.
The BMTH program was designed to support the development of the Australian medical device sector. By backing startups, entrepreneurs and smaller companies to bring life-saving products, process-improving products and improved monitoring and diagnostic products closer to market, we have demonstrated the potential of targeted medical research commercialisation programs via the MRFF to build stronger companies that are capable of tackling unmet clinical need.
Two impact reports highlight the program’s successes and showcase each projects’ innovations through case studies. The reports cover all elements of the program, detailing the activities and outcomes of each project and the program achievements overall.
As Australia’s life sciences industry accelerator, MTPConnect’s is backing Australian medical devices of the future through the BioMedTech Horizons Program. It’s …
Listen to Podcast
As Australia’s life sciences industry accelerator, MTPConnect’s is backing Australian medical devices of the future through the BioMedTech Horizons Program. It’s …
Listen to Podcast
